Proactive Investors - Run By Investors For Investors

Anatara Lifesciences transitions gut health focus from animals to humans

Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).
 
Lydeamore says the biotech firm's dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.
 
Anatara Lifesciences first came to prominence in developing a product to reduce diarrhoea in livestock.
 
Meet Xanadu Mines Ltd, Invitrocue Ltd, Infinity Lithium Corporation Ltd, Oventus Medical Ltd and Zelda Therapeutics Ltd at our event, Melbourne , 14 May 2019. Register here »
View full ANR profile View Profile

Anatara Lifesciences Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use